Dr. Clay Siegall Bats for Targeted Therapies in Cancer and Works on It

Dr. Clay Siegall, the founder and Chief Executive Officer of Seattle Genetics, is the proponent of targeted therapies in cancer, and he leads the team at his research firm to focus on result-oriented treatment. Seattle Genetics is a healthcare research firm which focuses on developing antibody-based targeted therapies to treat cancer. Dr. Clay Siegall is a critic of old style systemic chemotherapies and thinks that it is the time to put those types of treatments into the dustbin. He recalls that during his younger days, one of his relatives was treated for cancer, and the patient was going through brutal treatment regime. The experience led Dr. Siegall to focus his efforts to advance and simplify the treatment procedure that drives better results than almost killing them.


Dr. Siegall said that while he was venturing his own research firm, it took a lot of struggles to make the institution profitable. Especially during the initial years, the operating capital depleted multiple times, and as he was a workaholic person, he put his efforts to the work along with his colleagues and waited for time to come. Dr. Siegall thankfully remembers the dynamic sales staff of the firm, who turned things positive with their broad backgrounds in biotech. Apart from the sales team, the research team came up with some innovative products promptly and ensured a sustained growth of the firm. Dr. Siegall has all praise for hard work and states that it is the primary characteristic that differentiates humans from animals.


Dr. Siegall co-founded the firm in 1998 and developed it on the visions of rigorous research and scientific innovation to substantially increase the survival rate on some of the deadly diseases. His focused approach to providing better treatment solutions for cancer and other chronic diseases made the firm becoming the leader in antibody-drug conjugates (ADCs) for cancer treatment.


He is on the board of directors of some biotechnology firms and organizations including Alder Biopharmaceuticals Inc., Mirna Therapeutics, Inc., and Ultragenyx Pharmaceutical. Dr. Siegall completed his B.S. in Zoology from University of Maryland and later did his Doctor of Philosophy (Ph.D.) in Genetics from The George Washington University.


Eric Lefkofsky’s journey to philanthropy and investing

Steve Jobs and Bill Gates are primal CEOs and co-founders of their own companies, specializing in electronics and gadgets. But what this man does, however, is far more life changing. Eric Lefkofsky founded Tempus, an infamous technology company that has built an operating system that helps fight cancer. Mr Lefkofsky generated this system after his wife was diagnosed with breast cancer. He figured why one treatment for cancer would work for some but not all who tried it.

In addition to Tempus, Eric Lefkofsky takes home the bank by also being co-founder of Groupon, Lightbank, Uptake Technologies, Mediaocean, Echo Global Logistics, and also InnerWorkings. In addition to Lefkofsky’s many investments that are still being invested, he too started the Lefkofsky Family Foundation with his wife Elizabeth where it is a private charitable foundation. It is meant to improve the lives of communities served. Not only that, but Lefkofsky serves as a trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago.

Segueing back into Eric Lefkofsky’s business matters with diseases, he developed the idea for Tempus to be designed to layer on top electric medical record, or EMR, and pathology systems to composite the statistics, scrub it, and sustain the clean version back to each primary starting point for validation and verification. In the end, Eric Lefkofsky’s machine will ultimately help combine all data to differentiate between the patterns and end results.

Lefkofsky’s goal in creating Tempus is to give those who are just starting off in oncology and those working on neurological disorders a leg up and use the platform to collect data for analysis.

According to Lefkofsky, there isn’t a shortage of patient data in the midst, but there is, however, a lack of sources that combine both genomic information with therapeutic data.

Eric Lefkofsky has invested about 103 times within 74 companies. Not too shabby for a well aquaintedbusinessman. Lefkofsky does seem to be the blasé type —all of his success is essentially to help others in finding treatment. Lefkofsky’s philanthropy has helped many, including his public investments.